Ruxolitinib for tocilizumab-refractory severe COVID-19 infection

被引：31
|
作者：
Innes, Andrew J. [1 ,2 ]
Cook, Lucy B. [1 ,2 ]
Marks, Sasha [2 ]
Bataillard, Edward [2 ]
Crossette-Thambiah, Christina [2 ]
Sivasubramaniam, Gayathiri [3 ]
Apperley, Jane [1 ,2 ]
Milojkovic, Dragana [1 ,2 ]
机构：
[1] Imperial Coll London, Ctr Haematol, Dept Immunol & Inflammat, London, England
[2] Imperial Coll Healthcare NHS Trust, Dept Haematol, Hammersmith Hosp, London, England
[3] Imperial Coll Healthcare NHS Trust, Dept Resp Med, Hammersmith Hosp, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 190卷 / 04期
关键词：
transplant; infection; COVID-19; immunosupression;
D O I：
10.1111/bjh.16979
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E198 / E200
页数：3
相关论文
共 50 条
  • [1] Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
    de la Calle, Cristina
    Lopez-Medrano, Francisco
    Pablos, Jose Luis
    Lora-Tamayo, Jaime
    Maestro-de La Calle, Guillermo
    Sanchez-Fernandez, Marcos
    Fernandez-Ruiz, Mario
    Perez-Jacoiste Asin, Maria Asuncion
    Caro-Teller, Jose Manuel
    Garcia-Garcia, Rocio
    Catalan, Mercedes
    Martinez-Lopez, Joaquin
    Sevillano, Angel
    Origuen, Julia
    Ripoll, Mar
    San Juan, Rafael
    Lalueza, Antonio
    de Miguel, Borja
    Carretero, Octavio
    Aguilar, Fernando
    Gomez, Carlos
    Paz-Artal, Estela
    Bueno, Hector
    Lumbreras, Carlos
    Aguado, Jose Maria
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 105 : 319 - 325
  • [2] Ruxolitinib and Severe COVID-19
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    INFECTION AND CHEMOTHERAPY, 2021, 53 (04): : 796 - 796
  • [3] Tocilizumab in severe COVID-19
    Liberato, Nicola Lucia
    De Monte, Andrea
    Caravella, Giuseppe
    ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (06) : 1457 - 1458
  • [4] Tocilizumab for severe COVID-19 pneumonia
    Mourad, Jean-Jacques
    Azria, Philippe
    LANCET RHEUMATOLOGY, 2020, 2 (11): : E659 - E659
  • [5] The effect of tocilizumab on severe COVID-19 infection: Review of current evidence
    Yakar, Halil Ibrahim
    Pazarli, Ahmet Cemal
    Inonu Koseoglu, Handan
    Kanbay, Asiye
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2021, 69 (01): : 74 - 83
  • [6] Tocilizumab administration in a refractory case of COVID-19
    Dastan, Farzaneh
    Nadji, Seyed Alireza
    Saffaei, Ali
    Tabarsi, Payam
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (02)
  • [7] Effectiveness of tocilizumab in COVID-19 infection
    Romero Puerto, Javier
    Soria Martin, Alberto
    Garcia Marin, Javier
    Moreno Herrera, Adriana
    Fages Perez, Marina
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (06) : 1746 - 1747
  • [8] Repurposed Tocilizumab in Patients with Severe COVID-19
    Tian, Jianbo
    Zhang, Ming
    Jin, Meng
    Zhang, Fengqin
    Chu, Qian
    Wang, Xiaoyang
    Chen, Can
    Yue, Huihui
    Zhang, Li
    Du, Ronghui
    Zhao, Dong
    Zeng, Zhaofu
    Zhao, Yang
    Liu, Kui
    Wang, Mengmei
    Hu, Ke
    Miao, Xiaoping
    Zhang, Huilan
    JOURNAL OF IMMUNOLOGY, 2021, 206 (03): : 599 - 606
  • [9] Tocilizumab in severe COVID-19: A promise fulfilled
    Levi, Marcel
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 95 : 38 - 39
  • [10] Tocilizumab is recommended for the treatment of severe COVID-19
    Zhou, Yonggang
    Wei, Haiming
    EBIOMEDICINE, 2020, 61
12345